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Abstract All women in the South Sweden Health Care
Region with breast cancer diagnosed aged less than 41
during the period between 1990 and 1995 were contacted
in 1996 and offered germline mutation analysis of the
BRCA1 and BRCA2 genes. Mutation carriers (n = 20)
were compared with noncarriers (n = 201) for overall
survival (OS) and risk of contralateral breast cancer (CBC).
Mutation carriers were younger at diagnosis and more
likely to have ER-negative, PgR-negative and grade III
tumors. Median follow-up was 19 years. The 5-, 10-, 15-,
and 20-year OS were 60, 45, 39, and 39 % for mutation
carriers and 82, 70, 59, and 53 % for noncarriers, respec-
tively (5-year log-rank P = 0.013; 10-year P = 0.008;
15-year P = 0.020; and 20-year P = 0.046). In univariable
analysis, there was a trend for an inferior OS for mutation
carriers (HR 1.8; 95 % CI 1.0–3.3). When stratified for use
of (neo)adjuvant chemotherapy, an inferior OS was sig-
nificant only for the subgroup of patients who did not
receive chemotherapy (HR 3.0; 95 % CI 1.2–7.7). In
multivarible analysis, BRCA1/2 mutation status was a
significant predictor of OS when adjusting for tumor stage,
age, and use of chemotherapy, but not when ER status was
also included in the model. The 15-year cumulative risk of
CBC was 53 % for mutation carriers and 10 % for non-
carriers (HR 5.9; 95 % CI 1.9–18.6); among the noncarri-
ers the risks were 5, 22, and 30 % for patients without close
relatives having breast cancer, with second-degree relatives
having breast cancer, and with firstdegree relatives with
breast cancer, respectively. In conclusion, the poor prog-
nosis of young BRCA1/2 mutation carriers with breast
cancer is mainly explained by the prevalent occurrence of
negative prognostic factors rather than mutation status per
se, and can to at least some extent be abrogated by the use
of chemotherapy.
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Introduction
Breast cancer is a major cause of morbidity and death for
women all over the world. Approximately 5–10 % of
breast cancers are caused by the presence of constitutional
mutations in highly penetrant genes with autosomal dom-
inant inheritance. About half of these cases can be attrib-
uted to mutations in the tumor suppressor genes BRCA1 or
BRCA2 [1], the proportion varies depending on genetic
population, age of onset and family history. As opposed to
the relatively modest impact of hormonal and lifestyle risk
factors, a mutation in one of these two genes confers a
four- to eightfold increase in the lifetime risk of breast
M. P. Nilsson (&)  L. Hartman  N. Loman
Department of Oncology, Ska˚ne University Hospital, Clinical
Sciences, Lund University, S-221 85 Lund, Sweden
e-mail: martin.nilsson@med.lu.se
L. Hartman
Regional Cancer Centre, Clinical Sciences, Division of
Oncology, Lund University, Lund, Sweden
I. Idvall
Department of Pathology, Lund University, Lund, Sweden
U. Kristoffersson
Department of Clinical Genetics, Laboratory Medicine Region
Ska˚ne and Lund University, Lund, Sweden
O. T. Johannsson
Department of Oncology, Landspitali University Hospital,
Reykjavik, Iceland
123
Breast Cancer Res Treat (2014) 144:133–142
DOI 10.1007/s10549-014-2842-9
cancer [2, 3]. It also substantially increases the risk for
other cancers, in particular the ovarian cancer [4, 5]. Sev-
eral studies have found evidence for allelic risk heteroge-
neity, genetic modifiers, and hormonal and lifestyle factors
affecting penetrance [6–9]. This means that the setting in
which the mutation was detected, i.e., a clinical setting
within a family with several cancer cases or a population-
based setting, is important for cancer risks in the family
and possibly even for the prognosis of the cancers. Once a
mutation is found in a family, presymptomatic testing,
surveillance, and prophylactic surgery decrease the cancer-
specific mortality so that life expectancy approaches what
it is expected to be in the general population [10]. How-
ever, surveillance, and in particular prophylactic surgery,
may have a negative impact on various aspects of life and
health [11, 12]. In the end, it is up to the woman herself to
decide on what kind of measures she wants to take in order
to decrease her future risks of cancer. For that decision, it is
important to know whether the prognosis of a BRCA-
associated cancer is worse than, the same as, or better than
that for a sporadic cancer. Furthermore, for the oncologist,
it is important to know whether BRCA1/2 mutation status is
an independent prognostic factor, or even a predictive
factor, which should be taken into consideration when
decisions about treatment are taken.
It is now generally accepted that BRCA-associated
ovarian cancer is more sensitive to standard platinum-
based chemotherapy and has a superior, or rather less
adverse, prognosis (at least short term) than sporadic
ovarian cancer [13, 14]. For BRCA-associated breast
cancer, the prognosis remains a matter of debate, despite
many studies published over the last 15 years [15]. Such
studies should ideally report long-term follow-up, pri-
marily because breast cancer is a disease where late
recurrences are not unusual [16–18]. We conducted a
population-based study among young women with breast
cancer and a known BRCA1/2 mutation status. Our aims
were to assess overall survival and risk of contralateral
breast cancer.
Materials and methods
As previously reported [19], all women in the Southern
Health Care Region in Sweden with an invasive breast
cancer diagnosed with age less than 41 years during the
period between 1990 and 1995 (n = 262) were contacted
in 1996 and offered mutation analysis of the BRCA1 and
BRCA2 genes; 225 were then alive and 37 were dead.
Women who had died could be included if samples of their
blood or tissue were available in the tissue bank. Mutation
analysis was performed on 234 (89 %) of the patients,
including 33 of the patients that were not alive; the others
were excluded from further study. Mutation screening was
originally performed using protein truncation test, single-
strand conformation polymorphism, and denaturating high
performance liquid chromatography. Mutations were veri-
fied by sequencing. Some initially BRCA-negative families
with a strong family history of BRCA-associated cancer
have been reanalyzed at a later point of time. In two of
these families, pathogenic mutations were found, which
were not detectable with the above mentioned mutation-
screening protocol. They are now considered BRCA-
positive.
Twenty-three pathogenic mutations were found: 18 in
BRCA1 and 5 in BRCA2. Out of the 234 patients tested, 4
have declined further study follow-up or could not be
verified as having had an invasive breast cancer when
pathological reports were again reviewed, only carcinoma
in situ; these were therefore excluded. Six patients had
metastatic breast cancer at the time of diagnosis (one of
them being a BRCA2 mutation carrier) and were excluded.
Three patients were excluded since they had already had
another first primary breast cancer before 1990 (two of
them BRCA1 mutation carriers), leaving 221 for the present
analyses. Due to small numbers, BRCA1 (n = 16) and
BRCA2 (n = 4) mutation carriers were grouped together
for analyses. Current analyses were based on follow-up
information through January 31, 2012.
For the analysis of family history of breast cancer, infor-
mation about family history at the time of study inclusion
was collected from questionnaires and supplemented from
medical records. This information was then confirmed
independently in the National Swedish Cancer Register.
Therefore, the results concerning family history are to be
considered a minimum of the true figure in the families.
Clinical data were abstracted from medical records and
pathology reports. TNM stage was reclassified according to
American Joint Committee on Cancer 7th edition. Vital
status was controlled in the Swedish Census Register.
Study endpoints were overall survival (OS) and incidence
of contralateral breast cancer (CBC) for the pre-specified
subgroups of mutation carriers and of noncarriers. Breast
cancer specific survival (BCSS) was also analyzed. For CBC,
patients were regarded as censored at the time of prophylactic
mastectomy, death, distant spread of cancer, or date of last
follow-up. For CBC, both invasive breast cancer and DCIS
were included in the analyses. Age at diagnosis was stratified
into three age groups to account for nonlinear associations.
Selection of variables for exploratory subgroup analyses and
for multivariable analyses was based on results from previous
research. Tumor grade was not selected because of many
missing values, especially among mutation carriers. ER, but
not PgR, was considered for inclusion in the model.
Differences in tumor, patient, and treatment character-
istics between mutation carriers and noncarriers were
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tested using Fisher’s exact test for all covariates except for
age, where the difference in median age was tested using
the Wilcoxon rank sum test. For univariable analysis, OS
and CBC were estimated using the Kaplan–Meier method
and compared using the log-rank test. For the calculation of
hazard ratios and for multivariable analysis, the impact of
different prognostic factors on OS and CBC were assessed
by the Cox proportional hazards model. All tests were two-
tailed. All analyses were conducted using the R statistical
package. For the discussion part, P values below 0.05 were
considered statistically significant.
Results
Study population
Patient, tumor, and treatment characteristics are listed in
Table 1. Compared with noncarriers, mutation carriers were
younger at diagnosis (median 34.5 vs. 37.0 years;
P = 0.002) and more likely to have ER-negative (87 % vs.
46 %; P = 0.003), PgR-negative (80 % vs. 38 %;
P = 0.002) and grade III (83 % vs. 40 %; P = 0.005)
tumors. No difference was seen between the groups for TNM
Table 1 Patient, tumor, and
treatment characteristics
a Fisher0s exact test for all
b For patients alive at end of
follow-up
c (Neo)adjuvant neoadjuvant or
adjuvant. 2 carriers and 8
noncarriers received
neoadjuvant chemotherpy
Variable BRCA1/2 mutation carriers
(n = 20)
Noncarriers
(n = 201)
Pa
Median follow-upb, years 17.8 19.1
Age, years 0.004
Median 34.5 (range 23–39) 37.0 (range 24–40)
B 30 6 (30 %) 15 (7 %)
31–35 6 (30 %) 47 (23 %)
36–40 8 (40 %) 139 (69 %)
TNM stage 1
I 7 (35 %) 71 (35 %)
II 9 (45 %) 88 (44 %)
III 4 (20 %) 42 (21 %)
Tumor grade 0.021
I 1 (8 %) 40 (25 %)
II 1 (8 %) 57 (35 %)
III 10 (83 %) 65 (40 %)
Missing 8 39
ER status 0.003
Negative 13 (87 %) 79 (46 %)
Positive 2 (13 %) 93 (54 %)
Missing 5 29
PgR status 0.002
Negative 12 (80 %) 66 (38 %)
Positive 3 (20 %) 106 (62 %)
Missing 5 29
(Neo)adjuvant chemotherapyc 0.100
No 7 (35 %) 112 (56 %)
Yes 13 (65 %) 89 (44 %)
Adjuvant endocrine therapy 0.049
No 20 (100 %) 165 (83 %)
Yes 0 (0 %) 34 (17 %)
Family history of breast cancer 0.032
None 12 (63 %) 146 (74 %)
Second-degree relative 1 (5 %) 29 (15 %)
First-degree relative 6 (32 %) 21 (11 %)
Missing 1 5
Contralateral breast cancer 4 (all invasive) 13 (11 invasive)
Prophylactic contralateral mastectomy 5 6
Prophylactic or adjuvant oophorectomy 6 8
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stage (P = 1). Among mutation carriers, 13/20 (65 %)
received adjuvant or neoadjuvant chemotherapy, and none
received adjuvant endocrine treatment. Among noncarriers,
89/201 (44 %) received chemotherapy and 34/201 (17 %)
received endocrine treatment. Chemotherapy regimens used
were CMF-like (79 %), anthracycline-based (20 %) and
unknown type (1 %).
Overall survival
Median follow-up for OS was 19.0 years for women alive at
the end of follow-up. In univariable analysis, as seen in
Table 2, characteristics associated with an inferior OS in the
entire cohort were higher TNM stage (P \ 0.001), having
received (neo)adjuvant chemotherapy (P \ 0.001), and
having a PgR-negative tumor (P = 0.045). There was a
trend for a poorer prognosis for patients with ER-negative
tumors (P = 0.21). In the subgroup of noncarriers, also
younger age at diagnosis was associated with an inferior OS
(31–35 vs. 36–40 years HR 1.4; B30 vs. 36–40 years HR
2.5; P = 0.02). In the smaller subgroup of mutation carriers,
no markers were associated with a difference in OS (all
P [ 0.3 except for TNM stage where P = 0.08).
At the end of follow-up, 12/20 (60 %) mutation carriers
had died, all from breast cancer, whereas 94/201 (47 %) of
the noncarriers had died. There was a trend for worse survival
among mutation carriers compared with noncarriers (HR
1.8; 95 % CI 1.0–3.3) (Fig. 1). The 5-, 10-, 15-, and 20-year
OS was 60, 45, 39, and 39 % for mutation carriers and 82, 70,
59, and 53 % for noncarriers, respectively (5-year log-rank
P = 0.013; 10-year P = 0.008; 15-year P = 0.020; and
20-year P = 0.046). As seen in Fig. 2, for the subgroup of
patients with ER-negative tumors no difference in OS was
observed between mutation carriers and noncarriers (HR 1.3;
CI 0.6–2.8).
Out of the 12 mutation carriers who died, 11 died of
their first breast cancer and one had a distant recurrence of
breast cancer after having had a CBC; she probably died of
Table 2 Univariable analysis
for associations of variables
with overall survival
a Assessed by the Cox
proportional hazards model
Variable n patients n events HR 95 % CI P*
BRCA1/2 mutation status 0.053
Negative 201 94 1.0
Positive 20 12 1.8 1.0–3.3
Age, years 0.11
36-40 147 65 1.0
B 30 21 13 1.8 1.0–3.2
31-35 53 28 1.4 0.9–2.1
TNM stage
I 78 22 1.0 \0.001
II 97 50 2.1 1.3–3.5
III 46 34 5.2 3.0–8.9
Tumor grade 0.24
I or II 99 43 1.0
III 75 36 1.3 0.8–2.0
ER status 0.21
Negative 92 47 1.0
Positive 95 46 0.8 0.5–1.2
PgR status 0.045
Negative 78 42 1.0
Positive 109 51 0.7 0.4–1.0
(Neo)adjuvant chemotherapy \0.001
No 119 46 1.0
Yes 102 60 2.1 1.4–3.1
Adjuvant endocrine therapy 0.96
No 185 89 1.0
Yes 34 16 1.0 0.6–1.7
Family history of breast cancer 0.62
None 158 76 1.0
Second-degree relative 30 17 1.1 0.7–1.9
First-degree relative 27 10 0.8 0.4–1.5
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the CBC. Out of the 94 noncarriers who died, 82 died of
their first breast cancer, 4 had a distant recurrence of breast
cancer after having had a CBC, one died of a myocardial
infarction, 2 died of unknown causes (possibly breast
cancer), and 5 died of other malignancies (radiation-
induced pericardial mesothelioma, radiation-induced sar-
coma, colon carcinoma, cholangiocarcinoma, and ana-
plastic astrocytoma, respectively). Analysis of BCSS and
OS thus showed similar results (data not shown). None of
the 8 mutation carriers who was alive at the end of follow-
up had been diagnosed with ovarian cancer. Six of them
had a subsequent prophylactic oophorectomy at a median
of 9 years (range 1–18 years) after breast cancer diagnosis.
Among patients who received chemotherapy, mutation
carriers had a prognosis comparable to noncarriers (HR 1.1;
CI 0.5–2.5). Among patients who did not receive chemo-
therapy, mutation carriers had a worse prognosis compared
with noncarriers (HR 3.0; CI 1.2–7.7) (Figs. 3, 4). In this
subgroup no multivariable analysis or further stratification
was possible due to small numbers. Instead, factors with
known prognostic importance are listed in Table 3. As was
observed in the entire cohort, BRCA-associated tumors were
more likely to be grade III and ER-negative also in the
subgroup of patients that did not receive chemotherapy.
Multivariable analysis for OS was performed and
included mutation status, age, TNM stage and use of che-
motherapy (Table 4). In this model, mutation status and
TNM stage were associated with OS.
When ER status was also included in the model, only
TNM stage remained associated with OS at P \ 0.05 (data
not shown).
Contralateral breast cancer
The 15-year cumulative risk of CBC was 53 % for muta-
tion carriers and 10 % for noncarriers (HR 5.9; CI
1.9–18.6). Among noncarriers, the 15-year cumulative risk
of CBC was 5, 22, and 30 % for patients without close
relatives with breast cancer, for patients with second-
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degree relatives with breast cancer, and for patients with
first-degree relatives with breast cancer, respectively (sec-
ond-degree relative HR 4.7; CI 1.3–17.8, first degree rel-
ative HR 6.4; CI 1.7–23.9).
Discussion
In the present study, we compared the OS and the risk of CBC
between BRCA1/2 mutation carriers and noncarriers in a
population-based cohort of young women with early breast
cancer. In univariable analysis, a trend for an inferior OS was
seen for mutation carriers, and we could conclude that this
was not due to second primary tumors, e.g. ovarian cancers or
other competing deaths. When stratified for use of chemo-
therapy, the inferior OS was only significant for the subgroup
of patients who did not receive (neo)adjuvant chemotherapy.
It should be noted that both among patients who did and
among patients who did not receive (neo)adjuvant chemo-
therapy, BRCA-associated tumors were more often grade III
and ER-negative than non-BRCA-associated tumors. In
multivariable analysis, the inferior OS for mutation carriers
remained significant when adjusting for tumor stage, age and
chemotherapy. When ER status was included in the Cox
proportional hazards model, mutation status was no longer
significantly associated with OS, possibly due to the
decreased power with ER-status missing in 5/20 of the
mutation carriers. In this model, ER status was also not
associated with OS. We acknowledge that results from
multivariable analyses should be interpreted with caution in
small samples, and that the impact of ER status in particular
is difficult to assess due to missing values, few ER positive
tumors in the subgroup of mutation carriers, and inadequate
endocrine treatment.
The prognosis of BRCA-associated breast cancer has been
comprehensively summarized by Bordeleau et al. [15] in
2010. The authors concluded that most of the more recent
studies have failed to demonstrate a significant difference in
OS between mutation carriers and noncarriers. It is, however,
still a matter of debate whether the unadjusted or adjusted
prognosis is worse, the same, or better for mutation carriers
with breast cancer compared with sporadic cases. Multiple
studies, including our own, have found evidence for an
increased benefit of chemotherapy for mutation carriers
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Table 3 Important characteristics for patients that did not receive
(neo)adjuvant chemotherapy
Variable BRCA1/2 mutation
carriers (n = 7)
Noncarriers
(n = 112)
TNM stage
I 5 (71 %) 67 (60 %)
II 2 (29 %) 39 (35 %)
III 0 (0 %) 6 (5 %)
Tumor grade
I 0 (0 %) 31 (35 %)
II 1 (17 %) 33 (37 %)
III 5 (83 %) 25 (28 %)
Missing 1 23
ER status
Negative 4 (100 %) 30 (32 %)
Positive 0 (0 %) 63 (68 %)
Missing 3 19
Table 4 Multivariable analysis for overall survival
Variable HR 95 % CI Pa
BRCA1/2 mutation status 0.041
Negative 1.0
Positive 1.9 1.0–3.7
Age, years 0.16
36–40 1.0
B 30 1.2 0.6–2.2
31–35 1.6 1.0–2.5
TNM stage \0.001
I 1.0
II 2.2 1.3–3.9
III 6.1 3.1–12.1
(Neo)adjuvant chemotherapy 0.71
No 1.0
Yes 0.9 0.5–1.5
a Assesed by the Cox proportional hazards model adjusted for all
variables in Table 3
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compared with noncarriers. Two of these studies used a ret-
rospective anonymized design with analysis of Ashkenazi
founder mutations in archived paraffin-embedded tumor
blocks, avoiding survival bias and inclusion bias, but raising
questions about the generalizability to other populations.
Robson et al. [20] found that BRCA1 mutations were an
independent predictor of breast cancer mortality in univari-
able analysis. When stratified for chemotherapy, this inferior
prognosis was only seen in the subgroup that did not receive
chemotherapy, similar to the findings in our study. Rennert
et al. [21] found no difference in unadjusted or adjusted hazard
ratios for breast cancer mortality between mutation carriers
and noncarriers. For overall survival, they found an interaction
between BRCA1 mutation status and chemotherapy.
In 2012 and 2013, two studies have been published on the
issue of prognosis, which are superior to previous studies in
terms of adjustment for known prognostic factors and how
modern the given treatment was [22, 23]. In a prospective
cohort study, Goodwin et al. compared BRCA1/2 mutation
carriers with breast cancer to women with sporadic breast
cancer. The majority of the mutation carriers received
adjuvant chemotherapy. In univariable analysis, distant
recurrence and OS were inferior for BRCA2 mutation carri-
ers, but not for BRCA1 mutation carriers. After adjustment
for age, tumor stage and grade, nodal status, hormone
receptors, and year of diagnosis, the difference in distant
recurrence and OS between BRCA2 mutation carriers and
women with sporadic disease was no longer observed. The
authors concluded that the adverse prognosis for BRCA2
mutation carriers seems to depend on the presence of more
adverse tumor characteristics at diagnosis rather than
mutation status per se [22]. Huzarski et al. estimated a
10-year OS for breast cancer patients with a known BRCA1
Polish founder mutation status, and found no significant
difference in univariable analysis. In multivariable analysis,
which included most of the clinically important prognostic
factors apart from tumor grade, BRCA1 mutation carriers had
a poorer 10-year OS. They also found a significant interac-
tion between BRCA1 mutation status and effect of chemo-
therapy, meaning that the benefit of chemotherapy was
greater for mutation carriers than noncarriers [23].
We believe that the inferior prognosis for mutation
carriers seen in our study is mainly caused by the more
prevalent occurrence of negative prognostic factors, such
as ER-negativity and high tumor grade in the highly pro-
liferative BRCA-associated tumors [24]. Since ER-nega-
tivity is rather closely associated with high grade and high
proliferation, a simple way of visualizing this is to stratify
the cohort for ER status; the Kaplan–Meier curves for ER-
negative mutation carriers and ER-negative noncarriers are
similar (Fig. 2). Furthermore, this inferior prognosis for
mutation carriers can probably be abrogated by the use of
(neo)adjuvant chemotherapy, mainly because tumors with
BRCA-associated features such as high proliferation and
ER-negativity in general derive more absolute benefit from
chemotherapy [25, 26], but possibly also because BRCA1/2
deficiency per se is a predictive factor for sensitivity to
some types of chemotherapy [27, 28]. In the study by
Huzarski et al. [23], more than 90 % of the mutation car-
riers received chemotherapy, which is likely the reason
why no difference in OS was observed in univariable
analysis in their study.
Our study confirmed a high risk of CBC in BRCA1/2
mutation carriers with early-onset breast cancer; the
15-year risk was 53 %. Furthermore, among noncarriers
with a first- or second-degree relative with breast cancer an
increased risk of CBC was observed. This group of patients
is likely to include not only some women with mutations in
other highly penetrant or moderately penetrant breast
cancer genes, as well as some with an increased risk of
breast cancer in the family caused by multifactorial/poly-
genetic factors, but also a few women with a BRCA1/2
mutation that had evaded detection [29–32]. Rhiem et al.
[33] recently reported data on risk of CBC in a large cohort
of German breast cancer patients from high risk families
with a known BRCA1/2 mutation status. They found that
the 25-year cumulative risk of CBC was higher for non-
carriers with a first breast cancer before the age of 40 years
(28 %) than for mutation carriers with a first breast cancer
at the age of 50 years or later (BRCA1: 22 %; BRCA2:
16 %). For BRCA1-carriers with a first breast cancer before
the age of 40 years, the 25-year cumulative risk of CBC
was 55 %; for BRCA2-carriers it was 38 %. These results
are in line with the findings in our study, and has impli-
cations for the use of contralateral prophylactic mastecto-
mies in young breast cancer patients with BRCA1/2
mutations or a positive family history.
The strengths of our study are the population-based
design, its very high inclusion rate minimizing survival
bias and inclusion bias, the known BRCA1/2 mutation
status for all included patients, long follow-up time,
information on tumor and patient characteristics, treat-
ment, relapses and death. There are a number of limita-
tions: First and most notable a small number of patients.
Second, no separate analyses of BRCA1 and BRCA2
mutation carriers could be done. Third, the adjuvant
treatment that was given is now outdated. As an example,
adjuvant endocrine treatment was only given to a third of
the patients with ER-positive breast cancer; if all of them
would have received it, as is done today, the difference in
OS between mutation carriers and noncarriers would most
likely have been even more pronounced. On the other
hand, it is likely that modern chemotherapy regimens and
indications [25, 26], which are based on tumor biology
rather than tumor stage as was the case in the nineties,
would diminish the difference in OS between the groups.
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Recent studies have reported promising results for
mutation carriers treated with Cisplatin [28, 34] and PARP
inhibitors [35]. In future, these and other drugs might
render a better prognosis for at least some mutation carriers
compared with noncarriers.
However, despite the availability of modern treatment
regimens and more extensive use of chemotherapy, endo-
crine, and targeted therapy, the prognosis for young women
with breast cancer still remains unsatisfactorily poor. In the
case of BRCA1/2-associated breast and ovarian cancer,
identification of a mutation in the family makes presymp-
tomatic testing, surveillance, and prophylactic surgery
possible; these measures have a positive effect on the life
expectancy that is superior to the improvement in breast
and ovarian cancer prognosis that we have seen over the
last decades [10]. It is therefore very important to identify
mutation carriers.
In conclusion, early-onset breast cancer diagnosed in the
early nineties was associated with a poor prognosis. With
the limitation of a small study sample, our study suggests
that a positive BRCA1/2 mutation status is associated with
a pronounced severity of the prognosis, which may, how-
ever, be abrogated by the administration of (neo)adjuvant
chemotherapy. BRCA1/2 mutation carriers as well as
noncarriers with a positive family history indeed have an
increased risk of contralateral breast cancer compared with
patients with sporadic disease.
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